Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS formulation.

Abstract

An ALZA OROS drug delivery system was evaluated for its potential to increase drug load and reduce side effects when used with RWJ-333369 (S-2-O-carbamoyl-1-o-chlorophenyl-ethanol), a novel neuromodulatory agent initially developed by SK Bio-Pharmaceuticals and licensed by Johnson & Johnson. RWJ-333369 was found to have two crystalline polymorphs (A and B… (More)
DOI: 10.1016/j.ijpharm.2008.08.049

5 Figures and Tables

Topics

  • Presentations referencing similar topics